Pharmicell Co., Ltd. announced that it has received KRW 22 billion in funding from Samsung Securities Co. Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd., KB Securities Co., Ltd., Investment Arm
June 13, 2021
Share
On June 14, 2021, Pharmicell Co., Ltd. (KOSE:A005690) closed the transaction.
Pharmicell Co., Ltd. is a Korea-based company principally engaged in the biopharmaceutical business. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. It also provides steam cell storage services, and mesenchymal stem cells (MSCs) used for research areas and others. In addition, the Company engages in the fashion business, which provides womenâs and menâs apparels under the brand names of Religion and Day. On March 31, 2013, the Company merged with its wholly owned subsidiary, mainly engaged in the manufacture and sale of medicines.
Pharmicell Co., Ltd. announced that it has received KRW 22 billion in funding from Samsung Securities Co. Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd., KB Securities Co., Ltd., Investment Arm
PHARMICELL CO., LTD. 
